Skip to main content
Midas Edge

Tarsus Pharmaceuticals Inc

For the period ended Sep 30, 2024. Filed Nov 13, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 13, 2024

TARS$73.83+4.2%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Statements of Stockholders’ Equity

(In thousands, except share data)

Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Gain (Loss) · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance as of December 31, 202334,211,190$5$441,641$(2)$(244,656)$196,988
Net loss————(35,731)(35,731)
Recognition of stock-based compensation expense——5,519——5,519
Issuance of common stock, net of issuance costs of $6.7 million3,281,250198,328——98,329
Issuance of pre-funded warrants, net of issuance costs of $0.6 million——9,365——9,365
Exercise of vested stock options49,310—802——802
Issuance of common stock upon the vesting of restricted stock units207,718—————
Other comprehensive loss———(61)—(61)
Balance as of March 31, 202437,749,468$6$555,655$(63)$(280,387)$275,211
Net loss————(33,290)(33,290)
Recognition of stock-based compensation expense——7,481——7,481
Issuance of common stock upon public offering——3——3
Exercise of vested stock options99,678—1,818——1,818
Issuance of common stock upon the vesting of restricted stock units115,251—————
Shares issued in connection with the employee stock purchase plan65,988—1,136——1,136
Other comprehensive loss———(113)—(113)
Balance as of June 30, 202438,030,385$6$566,093$(176)$(313,677)$252,246
Net loss————(23,420)(23,420)
Recognition of stock-based compensation expense——7,415——7,415
Exercise of vested stock options58,674—721——721
Issuance of common stock upon the vesting of restricted stock units107,013—————
Other comprehensive gain———522—522
Balance as of September 30, 202438,196,072$6$574,229$346$(337,097)$237,484
Common Stock · Additional Paid-In Capital · Accumulated Other Comprehensive Loss · AccumulatedDeficit · TotalStockholders’Equity
Shares · Amount
Balance as of December 31, 202226,727,458$5$301,732$(74)$(108,763)$192,900
Net loss————(23,419)(23,419)
Recognition of stock-based compensation expense——3,906——3,906
Exercise of vested stock options6,443—13——13
Issuance of common stock upon the vesting of restricted stock units66,611—————
Other comprehensive gain———4—4
Balance as of March 31, 202326,800,512$5$305,651$(70)$(132,182)$173,404
Net loss————(31,424)(31,424)
Recognition of stock-based compensation expense——5,192——5,192
Exercise of vested stock options16,118—45——45
Issuance of common stock upon the vesting of restricted stock units45,653—————
Shares issued in connection with the employee stock purchase plan37,289—465——465
Other comprehensive gain———47—47
Balance as of June 30, 202326,899,572$5$311,353$(23)$(163,606)$147,729
Net loss————(39,148)(39,148)
Recognition of stock-based compensation expense——5,250——5,250
Issuance of common stock upon follow-on public offering, net of issuance costs of $6.9 million6,069,449—99,302——99,302
Exercise of vested stock options109,627—516——516
Issuance of common stock upon the vesting of restricted stock units25,439—————
Other comprehensive gain———15—15
Balance as of September 30, 202333,104,087$5$416,421$(8)$(202,754)$213,664
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.